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Abstract
Purpose Little research has been done to identify possible
cancer-related fatigue (CRF) subtypes and to classify cancer
survivors accordingly. We aimed to identify CRF subtypes in
a large population-based sample of (long term) stage I–III
colorectal cancer survivors. We also identified factors associ-
ated with the CRF subtypes.
Methods Respondents completed the Multidimensional
Fatigue Inventory and other validated questionnaires on anx-
iety and reduced positive affect (anhedonia), sleep quality, and
lifestyle factors (body mass index and physical activity).
Latent class analysis was used to derive the CRF subtypes.
Factors associated with the derived CRF subtypes were deter-
mined with multinomial logistic regression.
Results Three CRF classes were identified: class 1 (no fatigue
and distress, n = 644, 56%), class 2 (low fatigue, moderate
distress, n = 256, 22%), and class 3 (high fatigue, moderate
distress, n = 256, 22%). Multinomial logistic regression re-
sults show that survivors in class 3 were more likely to be
female, were treated with radiotherapy, have comorbid diabe-
tes mellitus, and be overweight/obese than survivors in class 1
(reference). Survivors in classes 2 and 3 were also more likely
to have comorbid heart condition, report poorer sleep quality,
experience anhedonia, and report more anxiety symptoms
when compared with survivors in class 1.
Conclusions Three distinct classes of CRF were identified
which could be differentiated with sleep quality, anxiety, an-
hedonia, and lifestyle factors.
Implications for cancer survivors The identification of CRF
subtypes with distinct characteristics suggests that interven-
tions should be targeted to the CRF subtype.
Keywords Cancer . Latent class analysis . Fatigue subtypes .
Population-based . Survivors
Introduction
Cancer survivors commonly experience fatigue. The preva-
lence of cancer-related fatigue (CRF) varies widely from
15–99%, depending on the domains of fatigue assessed, time
of assessment, and the questionnaire used [1]. However, for
approximately 30% of survivors, CRF persists long after treat-
ment completion [2]. CRF is defined as a subjective sense of
physical, emotional, and/or cognitive tiredness or exhaustion
related to cancer or cancer treatment that is not proportional to
exertion effort and interferes with usual functioning [3].
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Cancer survivors consider feeling fatigued as being more
of a burden and having a greater negative impact on daily
activities and health-related quality of life (HRQL) than other
distressing symptoms like pain and depression [4, 5]. Despite
its high prevalence and negative impact, CRF is still not well-
understood. The etiology of CRF is equivocal [6], although it
has been associated with cancer and its treatment [7]. CRF can
be hard to treat. Current CRF treatments such as pharmaco-
logical treatments [8], exercise [9], or psychosocial [10] inter-
ventions yield small to moderate effect sizes in meta-analyses.
A possible explanation for this limited treatment effect could
be that the concept of CRF is not optimally delineated, and
treatments are not targeted to patients’ specific fatigue
experiences.
CRF has been conceptualized as a multidimensional con-
cept, although there is discussion whether the dimensions of
fatigue are expressions of one symptom (multidimensional
concept) or expressions of separate symptoms such as physi-
cal or mental fatigue, collectively called fatigue (multiple
symptom concept) [11]. In qualitative studies, survivors de-
scribe their CRF as physical, cognitive, or emotional sensa-
tions of tiredness [12]. According to the multiple symptom
concept of fatigue, it is postulated that the dimensions of fa-
tigue will behave differently among cancer survivors. A re-
view found mixed results on the behaviors of physical and
mental fatigue among cancer survivors and healthy controls
[13]. Nevertheless, that review concluded there could be sup-
port for multiple symptom concept of fatigue as physical and
mental fatigue generally had different correlates, based on the
reviewed studies. A study that explored the fatigue experi-
ences of cancer survivors and patients with advanced cancer
found a weak correlation between physical and mental fatigue
among cancer survivors but no correlation between these two
dimensions of fatigue among patients with advanced cancer,
suggesting that these fatigue dimensions could be separate
phenomena among patients with advanced cancer [14].
Within the cancer survivor group, there was more heterogene-
ity in the relationship between physical and mental fatigue,
suggestive of different patterns of fatigue within this group.
However, little research has been done to classify cancer sur-
vivors according to CRF subtypes and to identify factors as-
sociated with the subtypes. In a study that focused only on
physical CRF, distinct predictors and trajectories of morning
and evening physical CRF were identified in on-treatment
patients [15, 16]. It is intuitive that better classification of
CRF can have implications for prognosis and response to
treatment. For example, it is possible that a survivor with
complaints of high physical and low mental CRF will benefit
more from an exercise intervention. On the other hand, a sur-
vivor with more complaints of mental CRF could improve
with psychosocial interventions.
In this exploratory analysis, our main study objective was
to identify possible CRF subtypes in a large population-based
sample of (long term) stage I–III colorectal cancer (CRC)
survivors. We will also identify factors associated with the
derived CRF subtypes and explore the association between
the CRF subtypes and HRQL.
Methods
Setting and participants
This study is part of a longitudinal, population-based survey
of all individuals living in the southern part of the Netherlands
who were diagnosed with CRC between 2000 and 2009, as
registered in the Netherlands Cancer Registry (NCR). The
NCR compiles data of all individuals newly diagnosed with
cancer in the Netherlands. The southern area covers 10 hospi-
tals serving 2.4 million inhabitants [17]. We excluded individ-
uals with cognitive impairment as indicated by the treating
medical specialist, had died prior to start of study (according
to the Central Bureau for Genealogy that collects information
on all deceased Dutch citizens via the civil municipal regis-
tries and hospital records), or had unverifiable addresses. A
complete overview of the sample selection can be found on
our website under Bdata and documentation^, http://www.
profilesregistry.nl/dataarchive/study_units/view/22.
Ethical approval for the study was obtained from a local
certified Medical Ethics Committee of the Maxima Medical
Centre Veldhoven.
Data collection
The study was started in December 2010, with yearly follow-
ups. In 2013, the Multidimensional Fatigue Inventory (MFI-
20) [18] was added to the standard questionnaire protocol. The
analyses presented in this paper used the MFI data collected at
this first assessment. Data were collected via PROFILES
(Patient Reported Outcomes Following Initial treatment and
Long term Evaluation of Survivorship). Details of the
PROFILES data collection method have been described
[19]. Briefly, eligible survivors received an invitation letter
with a link to a secure website, a login name, and a password
to provide informed consent and to complete questionnaires
online. Individuals without internet access, or who preferred
written rather than digital communication, could return a pre-
paid postcard requesting a pencil-and-paper version of the
informed consent and questionnaire. Non-respondents were
sent a reminder and questionnaire within 2 months.
Data from PROFILES studies are available for non-
commercial scientific research, subject to study question, pri-
vacy and confidentiality restrictions, and registration (www.
profilesregistry.nl) [19].
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Study measures
MFI-20
The MFI-20 consists of five scales assessing: general fatigue
(GF), physical fatigue (PF), reduced activity (RA), reduced
motivation (RM), and mental fatigue (MF) [18]. It comprises
20 items and responses are ranged on a 5-point scale. Higher
scores indicate more fatigue. The internal consistency of the
subscales was satisfactory, with Cronbach’s alpha coefficients
ranging from 0.79 to 0.93 [20].
Anxiety and depression (anhedonia)
The Hospital Anxiety and Depression Scale (HADS) com-
prises 14 items, 7 each assessing anxiety and depression
[21]. Items were scored on a 4-point scale, ranging from 0
to 3. For the anxiety subscale, total score was 21 and a cut-
off score ≥ 8 indicated clinical level of anxiety [21, 22]. To
reduce possible overlap of physical symptoms of depres-
sion with fatigue, we limited items to those assessing lack
of positive affect (i.e., anhedonia) [23]. This subscale con-
sists of 4 items: I look forward with enjoyment to things, I
feel cheerful, I can laugh and see the funny side of things,
and I still enjoy the things I used to enjoy (range 0–12,
mean + SD 2.2 ± 2.3). We defined anhedonia using a cut-
off score of ≥ 6 (i.e., one SD above the mean) from the total
score of the 4 items [24].
Sleep quality
Sleep quality was assessed with the Pittsburgh Sleep Quality
Index (PSQI) [25]. The PSQI consists of 19 items from which
7 component scores are derived: subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep distur-
bances, use of sleeping medication, and daytime dysfunction.
Although a total score of ≥ 5 indicates poor sleep [25], studies
suggest that a cut-off of 8 is more appropriate for cancer sur-
vivors [26].
Functioning and HRQL
We used the 5 functioning (physical, role, emotional, cogni-
tive, social) and the health status/overall quality of life scales
of the European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire version 3.0
(QLQ-C30) [27]. Items were scored on a scale from 1 (not at
all) to 4 (very much) which were linearly transformed to a 1–
100 scale following recommended guidelines [28]. Higher
scores indicate better functioning and HRQL.
Demographics, lifestyle, and clinical data
Self-reported demographic data included marital status,
weight, and height. BMI was calculated with self-reported
height and weight. On the validated European Prospective
Investigation into Cancer (EPIC) Physical Activity
Questionnaire [29], patients reported the average time spent,
during winter and summer, on walking, cycling, gardening,
household activities, and sports. Hours per week spent on
moderate-to-vigorous physical activity (MVPA) were derived
from estimated metabolic equivalent intensity values assigned
to each activity based on previously described classifications
[30, 31].
Self-reported comorbid status at the time of survey was
categorized according to the adapted Self-administered
Comorbidity Questionnaire (SCQ) [32].
Demographic and clinical information including date of
birth, date of diagnosis, cancer stage according to the tumor-
node-metastasis clinical classification [33], and treatment
were extracted from the NCR.
Statistical analyses
Differences in baseline characteristics of respondents, non-re-
spondents, and survivors with non-verifiable addresses were
determined using parametric tests (e.g., ANOVA) or non-
parametric equivalents (e.g., chi-square). As there were no
published cut-off scores of the MFI for cancer patients and
to facilitate interpretation of results in daily clinical practice,
we dichotomized the MFI scale scores using the 75th percen-
tile as cut-off (Table 1) to identify the survivors who were
fatigued. The cut-offs used in this study were comparable to
the mean MFI scores of cancer patients (including CRC) un-
dergoing chemotherapy [34]. We conducted latent class anal-
ysis using Latent GOLD 5.0 [35] to identify groups of survi-
vors with similar CRF profiles. Latent class analysis is a data-
driven approach that aims to obtain the smallest number of
groups with similar profiles based on a categorical latent var-
iable [36]. Using the 5 dichotomized MFI scores, we fitted
models with 1 to 8 classes. The optimal number of latent
classes was based on the model with the lowest Bayesian
information criterion (BIC) value, indicating the best fit.
Respondents were assigned to the class for which the posterior
probability was highest. The factors that discriminated the
identified classes were determined using multinomial logistic
regression on IBM SPSS (Statistical Package for Social
Sciences, Chicago, IL, USA) version 22 for Windows.
Differences in the mean HRQL scores between identified
CRF classes were determined with ANCOVA, correcting for
sex and age at survey. Post hoc analyses were conducted using
Bonferroni correction for multiple testing. All tests were two-
sided and significant if p < 0.05.
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Results
Participant characteristics
Of the 1465 stage I–III survivors eligible, 1183 (81%)
returned a questionnaire. There were no significant differences
in demographic and clinical characteristic differences between
respondents and non-respondents (Table 2).
Characteristics of identified CRF classes
Based on the lowest BIC (Table 3), a 3-class solution was
selected. Among the respondents, 27 (2%) were not classified
and were excluded from subsequent multinomial logistic re-
gression analyses. Of the 3-class model, class 1 (no fatigue
and distress, n = 644, 56%) was characterized by very low
scores on all MFI dimensions (Fig. 1). Class 2 (low fatigue,
moderate distress, n = 256, 22%) was characterized by low
scores on the three fatigue dimensions (GF, PF, MF) and mod-
erate reduction in activities and motivation (RA, RM) dimen-
sions. The third class (high fatigue, moderate distress, n = 256,
22%) was characterized by high general and physical fatigue,
and moderate reduction in activities and motivation but low
mental fatigue.
Factors associated with identified CRF classes
For the multinomial logistic regression models, class 1
(no fatigue and distress) was the reference group
(Table 4). In comparison with class 1, factors associated
with class 3 (high fatigue, moderate distress) were more
likely to be female sex, treatment with radiotherapy, co-
morbid diabetes mellitus, and being overweight/obese.
Survivors allocated to classes 2 (low fatigue, moderate
distress) and 3 were also more likely to have comorbid
heart condition, report poorer sleep quality, experience
anhedonia, and report more anxiety symptoms when com-
pared with those in class 1. When comparing factors that
differentiated between classes 2 and 3, being female and
reporting anhedonia symptoms were associated with sig-
nificantly lower chances of being in class 3.
Table 1 Distribution of
Multidimensional Fatigue
Inventory (MFI) dimension
scores of respondents (n = 1183)
MFI dimension range 4–20 Missing values Mean Median 75th interquartile score
General fatigue (GF) 13 9.73 9 13
Physical fatigue (PF) 14 9.69 9 13
Reduced activity (RA) 13 10.32 10 13
Reduced motivation (RM) 12 9.31 9 12
Mental fatigue (MF) 25 8.43 8 11
Higher MFI scores are indicative of fatigue severity
Table 2 Characteristics of
respondents and non-respondents N Respondents (n = 1183) Non-respondents (n = 282) p value
Mean age at survey ± SD 71.04 ± 9.2 70.38 ± 10.7 0.25
Mean years since diagnosis ± SD 8.16 ± 2.8 7.95 ± 2.8 0.34
Male (%) 687 (58) 169 (60) 0.57
Type of cancer (%) 0.34
Colon 702 (59) 176 (62)
Stage at diagnosis (%) 0.09
I 392 (33) 76 (27)
II 432 (37) 119 (42)
III 359 (30) 87 (31)
Treatment received 0.68
SU only 556 (47) 130 (46)
SU + RT 289 (25) 63 (22)
SU + CT 248 (21) 63 (22)
SU + RT + CT 89 (8) 26 (9)
SU surgery, RT radiotherapy, CT, chemotherapy
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Differences in functioning and HRQL
between the identified CRF classes
The EORTC-QLQ-C30 functioning and HRQL scores were
all significantly different between the three fatigue classes.
Survivors in class 1 (no fatigue and distress) scored the highest
on all functioning and HRQL subscales and class 3 (high
fatigue, moderate distress), the lowest (Fig. 2). Post hoc
Bonferroni tests between each of the three classes were all
significant at p < 0.0001 for all functioning and HRQL
subscales.
Discussion
This study, using a large population-based sample of stage
I-III (long term) CRC survivors, identified three classes of
CRF. More than half of the survivors were classified as
having no problems with fatigue or reduction in activities/
motivation. For the other two fatigued classes, differences
were found on severity of physical fatigue, and reduction
in activity and motivation levels rather than mental fa-
tigue. Our findings support previous research that pro-
posed that cancer survivors could have different patterns
of fatigue [14].
We found distinct characteristics in the identified CRF clas-
ses. Both classes 2 (low fatigue, moderate distress) and 3 (high
fatigue, moderate distress) have poorer quality of sleep, heart
problems, and anhedonia and anxiety symptoms in compari-
son with class 1 (no fatigue and distress). Although classes 2
and 3 are characterized by anhedonia and anxiety symptoms,
the lower levels of fatigue of survivors in class 2 suggest this
group is more likely to be depressed rather than fatigued. A
study that investigated the diagnostic reliability of a semi-
structured clinical interview for assessing fatigue in women
with chronic illnesses including cancer, found that fatigue
items were non-discriminatory between diagnostic groups
while symptoms such as anhedonia and loss of motivation
differentiated women with depression [37]. We cannot com-
pare our results with previous research as we were not able to
find published studies identifying CRF subtypes and their
associated variables.
Symptoms such as poorer quality of sleep, anxiety, and
depression commonly co-occur in cancer survivors [4], sug-
gesting a common biological mechanism underlying these
symptoms [38]. Increased levels of inflammation have been
shown to be associated with fatigue, insomnia, and depression
in breast cancer survivors [39], and fatigue and disturbed sleep
among metastatic CRC patients [40]. Genetic associations be-
tween the IL-6 gene with fatigue and sleep disturbance were
found among breast cancer patients [41].
Being overweight/obese was associated with higher odds
of being classified in class 3 (high fatigue, moderate distress).
This is in line with previous research [42, 43], highlighting the
need for interventions to improve survivors’ self-management
strategies for a healthier survivorship.
Using theMFI, we found distinct CRF classes among long-
term CRC survivors. Future research using different question-
naires or samples (e.g., incident cancer patients) should be
conducted to replicate our findings. Longitudinal studies
could also investigate whether identified CRF subtypes re-
main stable or change during follow-up as this could have
implications when developing interventions. We do not have
biological data to explore the possibility of inflammation un-
derlying the association between fatigue and other symptoms
such as poor sleep, depression, and anxiety. In our new
Table 3 Optimal number of clusters according to Bayesian Information
Criterion (BIC) scores
Model BIC p value Entropy
2-cluster 5699.0855 9.8e-16 0.8313
3-cluster 5643.3933 0.011 0.7317
4-cluster 5659.0827 0.48 0.7293
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Fig. 1 Mean scores of the
Multidimensional Fatigue
Inventory scales for each of the 3
identified fatigue classes
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Table 4 Odd ratios and 95% confidence interval of factors associated with latent classes of cancer-related fatigue
Factors Class 1 (n = 644) versus class 2 (n = 256) Class 1 versus class 3 (n = 256) Class 2 versus class 3
Demographics
Age (years)
< 65 – – –
≥ 65 0.94 (0.64–1.39) 0.65 (0.42–1.01) 0.74 (0.45–1.23)
Gender
Male – – –
Female 1.03 (0.71–1.49) 1.83 (1.19–2.80) 1.87 (1.16–3.01)
In a partnered relationship
Yes – – –
No 0.85 (0.55–1.30) 1.26 (0.79–2.01) 1.39 (0.81–2.49)
Clinical
Years since diagnosis
< 10 – – –
≥ 10 0.81 (0.56–1.18) 0.78 (0.50–1.22) 1.01 (0.61–1.68)
Chemotherapy
No – – –
Yes 1.24 (0.86–1.79) 1.29 (0.84–1.99) 1.01 (0.65–1.74)
Radiotherapy
No – – –
Yes 1.18 (0.83–1.69) 1.57 (1.04–2.37) 1.43 (0.89–2.31)
Comorbid heart conditions
No – – –
Yes 1.63 (1.05–2.52) 2.47 (1.51–4.03) 1.53 (0.89–2.65)
Comorbid diabetes mellitus
No – – –
Yes 1.55 (0.93–2.59) 2.60 (1.50–4.48) 1.65 (0.90–3.01)
Psychosomatic
Sleep problems
No – – –
Yes 2.28 (1.50–3.48) 3.28 (2.09–5.17) 1.58 (0.98–2.55)
Anhedonia symptoms
No – – –
Yes 3.98 (1.50–10.51) 20.61 (8.54–49.74) 5.18 (2.53–10.63)
Anxiety symptoms
No – – –
Yes 1.89 (1.15–3.10) 2.53 (1.50–4.26) 1.35 (0.78–2.35)
Lifestyle
Body mass index
Underweight/normal – – –
Overweight/obese 1.40 (0.97–2.03) 1.60 (1.03–2.49) 1.08 (0.66–1.78)
Moderate-to-vigorous physical activitya
Adequate – – –
Inadequate 1.02 (0.52–1.99) 0.66 (0.34–1.28) 0.69 (0.33–1.46)
Class 1: no fatigue and distress
Class 2: low fatigue, moderate distress
Class 3: high fatigue, moderate distress
a Dutch guidelines recommend 150 min/week
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prospective study on incident CRC patients, we are including
the collection of biological data.
We identified three distinct latent classes of CRF. Sleep
quality, anxiety, anhedonia, and lifestyle factors significantly
differentiated the identified CRF subtypes. Survivors with the
highest levels of fatigue and reduced activity and motivation
had the lowest HRQL scores. The identification of CRF sub-
types with distinct characteristics suggests that interventions
should be specific for the CRF subtype. A recent meta-
analysis reported that cognitive behavioral therapy or exercise
intervention was superior to pharmaceutical treatments in re-
ducing fatigue among cancer survivors [44]. For example,
survivors characterized by high levels of distress or sleep
problems could benefit more from cognitive behavioral ther-
apy [45, 46] or mindfulness-based therapy [47]. Survivors
with a low activity pattern could profit more from exercise
interventions [9, 48].
Several limitations of this study have to be considered.
We report results from a cross-sectional study as we only
have MFI data from one data point. As such, the results of
this exploratory study should be cautiously interpreted.
Although the MFI purports to assess five dimensions of
fatigue, these dimensions have not been wholly replicated
[49]. Nevertheless, in this exploratory study, we identified
three classes of CRF that had different associations with
sleep quality, anxiety, anhedonia, and lifestyle factors.
Dichotomizing the MFI scale scores could reduce the in-
formation available [50]. Potential loss of power from
dichotomizing could be mitigated by our large sample
size. We used the 75th IQR range as a cut-off for the
MFI as there was no published cut-offs for cancer pa-
tients. Published cut-off scores were available only on
the general fatigue and reduced activity dimensions in a
study of individuals with chronic fatigue syndrome [51].
The cut-offs we used were comparable to those used in
that study and to the mean fatigue scores of cancer pa-
tients (including CRC) undergoing chemotherapy [34].
Furthermore, our sample included long-term survivors
which could introduce survivorship bias, i.e., causes of
fatigue might not be necessarily cancer-related but could
be due to aging and other comorbid conditions. However,
time since diagnosis was not associated with the latent
classes of CRF. We do not have data on disease progres-
sion so we cannot rule out the possibility that some sur-
vivors could be under active treatment for disease pro-
gression at the time of survey. If so, this could influence
the fatigue scores.
In conclusion, three distinct classes of CRF were identified
which could be differentiated with sleep quality, anxiety, an-
hedonia, and lifestyle factors. Better classification of patients
and tailoring interventions to patients’ fatigue experiences
could enhance the effectiveness of beneficial interventions
for CRF currently developed.
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